Event-Free Survival Extended With Long-Term Finerenone in Heart Failure
MONDAY, Sept. 30, 2024 -- Long-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according to a brief report published online Sept. 27 in JAMA Cardiology to coincide with the annual meeting of the Heart Failure Society of America, held virtually from Sept. 27 to 30.
Muthiah Vaduganathan, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues estimated the long-term treatment effects of finerenone if treated during a patient's lifetime in patients with heart failure with mildly reduced or preserved ejection fraction. Analyses included data from the FINEARTS-HF trial, which was conducted in 37 countries across 653 sites. Participants, who were aged 40 years and older and had symptomatic heart failure and left ventricular ejection fraction of 40 percent or higher, were randomly assigned to finerenone (titrated to 20 or 40 mg) or placebo; 6,001 participants were included in the analysis.
The researchers found that for a 55-year-old participant, mean survival free from the primary composite outcome of time to cardiovascular death or worsening heart failure event was 13.6 and 10.5 years with finerenone and placebo, respectively, representing a gain of 3.1 years in event-free survival. For a 65-year-old participant, mean event-free survival was 11.0 and 8.9 years with finerenone and placebo, respectively, representing a gain of 2.0 years. For every starting age between 50 and 80 years, the projected mean event-free survival was numerically greater with finerenone versus placebo. Even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor, there were lifetime gains in event-free survival observed (3.1 years for a 65-year-old participant).
"The relative benefits reported during follow-up in the FINEARTS-HF trial can be interpreted together with these new projections of the expected absolute benefits with lifetime use of finerenone," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Bayer, which manufactures finerenone and funded FINEARTS-HF.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
First Heart Failure Hospitalization Occurs Earlier for Some Racial, Ethnic Groups
MONDAY, Sept. 8, 2025 -- First heart failure hospitalization occurs at a significantly younger age for non-Hispanic (NH) Asian, NH Black, and Hispanic adults than for NH White...
β-Blockers Not Beneficial After MI Without Reduced Left Ventricular Ejection Fraction
TUESDAY, Sept. 2, 2025 -- For patients with acute myocardial infarction (MI), beta-blockers are not beneficial in those without reduced left ventricular ejection fraction (LVEF)...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 -- Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.